| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1012611530 |
| P356 | DOI | 10.1186/1475-2875-8-63 |
| P932 | PMC publication ID | 2678145 |
| P698 | PubMed publication ID | 19366448 |
| P5875 | ResearchGate publication ID | 24277599 |
| P50 | author | Ogobara K. Doumbo | Q3349810 |
| Stephen Rulisa | Q53086508 | ||
| Issaka Sagara | Q72250521 | ||
| Hamma Maiga | Q72250613 | ||
| Alassane Dicko | Q72250716 | ||
| Niawanlou Dara | Q114402286 | ||
| Kourane Sissoko | Q125294545 | ||
| Abdoulaye A. Djimde | Q28913759 | ||
| Wilfred Fomban Mbacham | Q44156522 | ||
| Ishag Adam | Q47149235 | ||
| P2093 | author name string | F Herwig Jansen | |
| Oumar B Traore | |||
| Yahia T Dicko | |||
| P2860 | cites work | Malaria | Q55878749 |
| Comparison of different artemisinin-based combinations for the treatment of Plasmodium falciparum malaria in children in Kigali, Rwanda, an area of resistance to sulfadoxine-pyrimethamine: artesunate plus sulfadoxine/pyrimethamine versus artesunate | Q81542344 | ||
| The global distribution of clinical episodes of Plasmodium falciparum malaria | Q24599466 | ||
| Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial | Q28469217 | ||
| Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster | Q29614923 | ||
| Epidemiology of drug-resistant malaria | Q30830669 | ||
| Artesunate and dihydroartemisinin (DHA): unusual decomposition products formed under mild conditions and comments on the fitness of DHA as an antimalarial drug | Q31121606 | ||
| The economic burden of malaria. | Q34292910 | ||
| A fixed-dose 24-hour regimen of artesunate plus sulfamethoxypyrazine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan | Q35017456 | ||
| Artemether-lumefantrine for uncomplicated malaria: a systematic review | Q35709551 | ||
| Antimalarial combinations | Q35840382 | ||
| A comparative study on the efficacy of artesunate plus sulphadoxine/pyrimethamine versus artemether-lumefantrine in eastern Sudan | Q35925276 | ||
| Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa | Q36465190 | ||
| Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. | Q36937442 | ||
| Chemical instability determines the biological action of the artemisinins | Q37066126 | ||
| Artesunate and sulfadoxine-pyrimethamine combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Uganda: a randomized, double-blind, placebo-controlled trial | Q38881940 | ||
| The efficacy of antimalarial monotherapies, sulphadoxine–pyrimethamine and amodiaquine in East Africa: implications for sub‐regional policy | Q38882717 | ||
| Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria | Q39188623 | ||
| A randomized, placebo-controlled, double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria | Q39257146 | ||
| Efficacy of chloroquine and sulfadoxine/pyrimethamine mono- and combined therapy against falciparum malaria in Sudan. | Q40448284 | ||
| Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria | Q40510491 | ||
| Molecular diagnosis of resistance to antimalarial drugs during epidemics and in war zones | Q41913694 | ||
| Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. | Q41914794 | ||
| Assessment of the relative advantage of various artesunate-based combination therapies by a multi-treatment Bayesian random-effects meta-analysis. | Q41941734 | ||
| The efficacy of sulfadoxine-pyrimethamine alone and in combination with chloroquine for malaria treatment in rural Eastern Sudan: the interrelation between resistance, age and gametocytogenesis | Q41945474 | ||
| Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial | Q43972330 | ||
| Single-day, three-dose treatment with fixed dose combination artesunate/sulfamethoxypyrazine/pyrimethamine to cure Plasmodium falciparum malaria | Q46152786 | ||
| A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. | Q46266769 | ||
| Molecular epidemiology of malaria in Cameroon. XXVII. Clinical and parasitological response to sulfadoxine-pyrimethamine treatment and Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase alleles in Cameroonian children | Q47838452 | ||
| A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali. | Q48036406 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | malaria | Q12156 |
| Plasmodium falciparum | Q311383 | ||
| pyrimethamine | Q421072 | ||
| artesunate | Q707939 | ||
| lumefantrine | Q904464 | ||
| P304 | page(s) | 63 | |
| P577 | publication date | 2009-04-14 | |
| P1433 | published in | Malaria Journal | Q15749954 |
| P1476 | title | Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial | |
| P478 | volume | 8 |
| Q57022540 | A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali |
| Q38480612 | A single, low, oral dose of a 5-carbon-linked trioxane dimer orthoester plus mefloquine cures malaria-infected mice |
| Q34506787 | An open randomized clinical trial in comparing two artesunate-based combination treatments on Plasmodium falciparum malaria in Nigerian children: artesunate/sulphamethoxypyrazine/pyrimethamine (fixed dose over 24 hours) versus artesunate/amodiaquine |
| Q38497186 | Antimalarial Preclinical Drug Development: A Single Oral Dose of A 5-Carbon-linked Trioxane Dimer Plus Mefloquine Cures Malaria-Infected Mice |
| Q37388596 | Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria |
| Q34267667 | Artemether-lumefantrine: an option for malaria |
| Q39042892 | Coartem(®): a decade of patient-centric malaria management |
| Q38642887 | Comparison of anti-malarial drugs efficacy in the treatment of uncomplicated malaria in African children and adults using network meta-analysis |
| Q42957855 | Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan |
| Q47983515 | Effectiveness of ACTs in cases of resistance to partner drugs |
| Q37525389 | Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central Afri |
| Q38895510 | Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis |
| Q53702337 | Efficacy and safety of artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Sudan: a systematic review and meta-analysis. |
| Q36459402 | Efficacy of artemether-lumefantrine as a treatment for uncomplicated Plasmodium vivax malaria in eastern Sudan |
| Q28476262 | Efficacy of artesunate + sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children |
| Q42939143 | Efficacy of artesunate with sulfalene plus pyrimethamine versus praziquantel for treatment of Schistosoma mansoni in Kenyan children: an open-label randomised controlled trial |
| Q47995732 | Establishing pharmacovigilance programs in resource-limited settings: the example of treating malaria |
| Q92463531 | How delayed and non-adherent treatment contribute to onward transmission of malaria: a modelling study |
| Q34478487 | Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines |
| Q36644511 | In Vivo Efficacy and Parasite Clearance of Artesunate + Sulfadoxine-Pyrimethamine Versus Artemether-Lumefantrine in Mali |
| Q35186075 | In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Central Ethiopia |
| Q34809408 | Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination |
| Q36075976 | Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border. |
| Q38645449 | Malaria-Infected Mice Are Cured by a Single Low Dose of a New Silylamide Trioxane Plus Mefloquine |
| Q42021778 | Malaria-infected mice live until at least day 30 after a new monomeric trioxane combined with mefloquine are administered together in a single low oral dose |
| Q33559071 | Molecular correlates of high-level antifolate resistance in Rwandan children with Plasmodium falciparum malaria |
| Q64257418 | Monitoring the Efficacy and Safety of Artemisinin-Based Combination Therapies: A Review and Network Meta-analysis of Antimalarial Therapeutic Efficacy Trials in Cameroon |
| Q37857327 | Novartis Malaria Initiative: best practice example of pharmaceutical industry's engagement in the fight against malaria |
| Q37263818 | Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda |
| Q34398049 | Plasmodium falciparum clearance with artemisinin-based combination therapy (ACT) in patients with glucose-6-phosphate dehydrogenase deficiency in Mali |
| Q37366055 | Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda |
| Q36411652 | Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda |
| Q35094826 | Protection of Malian children from clinical malaria is associated with recognition of multiple antigens |
| Q36080127 | Repeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impact |
| Q30592761 | Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials |
| Q35770484 | Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Enfranze, north-west Ethiopia |
| Q47124275 | Therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Ethiopia: a systematic review and meta-analysis |
Search more.